Profund Advisors Boosted Fifth Third Bancorp (FITB) Holding; Array Biopharma (ARRY) Shorts Decreased By 2.18%

September 11, 2017 - By Nellie Frank

Profund Advisors Llc increased Fifth Third Bancorp (FITB) stake by 68.95% reported in 2016Q4 SEC filing. Profund Advisors Llc acquired 19,468 shares as Fifth Third Bancorp (FITB)’s stock declined 12.20%. The Profund Advisors Llc holds 47,705 shares with $1.29M value, up from 28,237 last quarter. Fifth Third Bancorp now has $18.98 billion valuation. The stock rose 2.63% or $0.66 reaching $25.76 per share. About 2.10M shares traded. Fifth Third Bancorp (NASDAQ:FITB) has risen 33.30% since September 11, 2016 and is uptrending. It has outperformed by 16.60% the S&P500.

Array Biopharma Incorporated (NASDAQ:ARRY) had a decrease of 2.18% in short interest. ARRY’s SI was 20.56 million shares in September as released by FINRA. Its down 2.18% from 21.02 million shares previously. With 2.45 million avg volume, 8 days are for Array Biopharma Incorporated (NASDAQ:ARRY)’s short sellers to cover ARRY’s short positions. The SI to Array Biopharma Incorporated’s float is 14.33%. About 12.96M shares traded or 246.52% up from the average. Array Biopharma Inc (NASDAQ:ARRY) has risen 176.51% since September 11, 2016 and is uptrending. It has outperformed by 159.81% the S&P500.

Investors sentiment decreased to 1.16 in 2016 Q4. Its down 0.16, from 1.32 in 2016Q3. It is negative, as 34 investors sold Array Biopharma Inc shares while 36 reduced holdings. 36 funds opened positions while 55 raised stakes. 158.02 million shares or 7.81% more from 146.57 million shares in 2016Q3 were reported. 19,500 are held by Janney Montgomery Scott Lc. New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.1% in Array Biopharma Inc (NASDAQ:ARRY). Art Ltd Co stated it has 0.03% in Array Biopharma Inc (NASDAQ:ARRY). Deerfield Co has 0.6% invested in Array Biopharma Inc (NASDAQ:ARRY). Dekabank Deutsche Girozentrale has 0.01% invested in Array Biopharma Inc (NASDAQ:ARRY) for 70,000 shares. Trexquant Inv L P has invested 0.06% in Array Biopharma Inc (NASDAQ:ARRY). Goldman Sachs stated it has 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY). Nationwide Fund Advsrs owns 0.01% invested in Array Biopharma Inc (NASDAQ:ARRY) for 139,267 shares. Aqr Management Limited Co reported 131,012 shares stake. Macquarie Group Inc Limited accumulated 0.01% or 330,000 shares. State Street Corp owns 6.43 million shares or 0.01% of their US portfolio. Northern Tru stated it has 1.95 million shares or 0.01% of all its holdings. Tiaa Cref Mngmt Limited Liability Corp owns 751,440 shares for 0% of their portfolio. Cubist Systematic Strategies Ltd Company invested in 4,400 shares. Geode Cap Mgmt Ltd Liability Corp invested in 0.01% or 1.45 million shares.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Array BioPharma had 21 analyst reports since June 3, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 5 by Stifel Nicolaus. The rating was maintained by Cowen & Co with “Buy” on Wednesday, August 9. The firm has “Buy” rating given on Thursday, August 24 by Jefferies. The rating was downgraded by JP Morgan on Friday, February 3 to “Neutral”. The stock has “Buy” rating by Stifel Nicolaus on Friday, February 3. As per Thursday, July 13, the company rating was maintained by Jefferies. Piper Jaffray maintained Array Biopharma Inc (NASDAQ:ARRY) on Monday, September 26 with “Overweight” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, August 9. The stock of Array Biopharma Inc (NASDAQ:ARRY) earned “Buy” rating by SunTrust on Friday, June 3. Cantor Fitzgerald maintained Array Biopharma Inc (NASDAQ:ARRY) on Tuesday, May 30 with “Buy” rating.

Array BioPharma Inc. is a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The company has market cap of $1.83 billion. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib . It currently has negative earnings. The Company’s binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC).

Since March 28, 2017, it had 0 insider buys, and 2 selling transactions for $633,150 activity. LEFKOFF KYLE sold $401,400 worth of stock or 45,000 shares. $231,750 worth of stock was sold by BAUM CHARLES M on Tuesday, March 28.

Since April 28, 2017, it had 0 insider buys, and 4 sales for $1.32 million activity. On Friday, April 28 Hoover Jewell D sold $49,632 worth of Fifth Third Bancorp (NASDAQ:FITB) or 2,000 shares. Leonard James C. sold 15,000 shares worth $373,200. Tanner Teresa J. had sold 26,010 shares worth $647,649 on Thursday, May 4. ANDERSON LARS C had sold 10,079 shares worth $247,943 on Friday, April 28.

Among 29 analysts covering Fifth Third (NASDAQ:FITB), 5 have Buy rating, 2 Sell and 22 Hold. Therefore 17% are positive. Fifth Third had 68 analyst reports since July 22, 2015 according to SRatingsIntel. The company was upgraded on Monday, May 16 by Wood. Piper Jaffray maintained Fifth Third Bancorp (NASDAQ:FITB) on Tuesday, August 15 with “Hold” rating. The stock of Fifth Third Bancorp (NASDAQ:FITB) earned “Buy” rating by RBC Capital Markets on Thursday, July 27. The rating was upgraded by Bernstein on Wednesday, August 26 to “Mkt Perform”. Keefe Bruyette & Woods maintained Fifth Third Bancorp (NASDAQ:FITB) on Wednesday, August 23 with “Hold” rating. The stock of Fifth Third Bancorp (NASDAQ:FITB) has “Buy” rating given on Thursday, September 7 by RBC Capital Markets. RBC Capital Markets maintained Fifth Third Bancorp (NASDAQ:FITB) on Thursday, June 22 with “Buy” rating. Jefferies downgraded Fifth Third Bancorp (NASDAQ:FITB) on Friday, October 7 to “Hold” rating. As per Monday, October 10, the company rating was downgraded by Nomura. The stock has “Hold” rating by Jefferies on Friday, August 11.